混合型肝细胞肝癌-胆管细胞癌的手术治疗及影响预后的因素  

An analysis of treatment and factors influencing on the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma

作　　者：周元[1] 徐爱兵[1] 邵冰峰[1] 张一心[1] 蔡鸿宇[1] 

机构地区：[1]南通市肿瘤医院肝胆外科,江苏省226300

出　　处：《江苏医药》2015年第13期1517-1519,共3页Jiangsu Medical Journal

摘　　要：目的探讨混合型肝细胞肝癌-胆管细胞癌(cHCC-CC)的治疗及影响其预后的因素。方法复习手术治疗cHCC-CC 25例的临床资料,分析影响其预后的因素。结果 25例患者的诊断均经手术切除标本病理证实。术后随访,14例获得再治疗。单因素分析显示,甲胎蛋白(AFP)水平、脉管内癌栓、淋巴结转移和肿瘤直径是影响累计生存率的重要因素。多因素分析显示,肿瘤直径和AFP是影响预后的独立危险因素。结论 cHCC-CC以手术治疗为主,但复发率高,预后差;采取多元化抗肿瘤治疗可提高术后生存期。Objective To analyze the treatment and factors influencing on the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma（cHCC-CC）.Methods Clinical data of 25 cases with cHCC-CC underwent hepatectomy were reviewed and the factors influencing on the prognosis were retrospectively analyzed.Results The diagnosis of cHCC-CC was confirmed pathologically after surgery in 25 cases.The patients were followed up,of whom 14 cases received retreatment.Single factor analysis showed that serum level of alpha fetus protein（AFP）,vascular tumor emboli,lymph node metastasis,and tumor diameter were the important factors affecting the cumulative survival rate.Multiple factors analysis showed that tumor diameter and AFP were the independent factors influencing on the prognosis of patients with cHCC-CC.Conclusion Surgery is the main treatment of cHCC-CC,but the recurrence rate is high and the prognosis is poor.The postoperative survival can be improved by adopting diversified anti-tumor treatments.

关 键 词：混合型肝细胞-胆管细胞癌 

分 类 号：R735[医药卫生—肿瘤]